Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR
SKBBYDrugs in Pipeline
63
Phase 3 Programs
32
Upcoming Catalysts
42
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
42 upcoming, 2 past
Wujia Yizhi granules
Alzheimer's Dementia
Nab-paclitaxel
Triple Negative Breast Cancer
Topotecan
Small Cell Lung Cancer
HSK3486
Sedation or Anesthesia
Capecitabine
Metastatic Breast Cancer
Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel
HER2-low Breast Cancer
Docetaxel
Non-small Cell Lung Cancer
Docetaxel or Paclitaxel
Urothelial Carcinoma
Eribulin
HR+HER2- Breast Cancer
Propofol
Colonoscopy
Paclitaxel
Head and Neck Squamous Cell Carcinoma
SKB264
Metastatic Breast Cancer
Pemetrexed
Non-small Cell Lung Cancer
Osimertinib
Non-Small Cell Lung Cancer
Vinorelbine
Triple-Negative Breast Cancer
SI-B001
Non-small Cell Lung Adenocarcinoma
BL-M07D1
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
A166
HER2-positive Breast Cancer
Irinotecan
Esophageal Squamous Cell Carcinoma
T-DM1
HER2-positive Breast Cancer
gemcitabine
Nasopharyngeal Carcinoma
KN035 plus Gemcitabine & oxaliplatin
Biliary Tract Neoplasms
Investigator's choice of chemotherapy
Gastric Adenocarcinoma
Pemetrexed+Cisplatin or Carboplatin
Non-small Cell Lung Cancer
BL-B01D1
Advanced Biliary Tract Cancer
Carboplatin
Non-squamous Non-small Cell Lung Cancer
BL-M05D1
Gastric Cancer
carboplatin or cisplatin
Non-Small Cell Lung Cancer
Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
Non-small Cell Lung Cancer
Pertuzumab
HER2-positive Breast Cancer
KL-A167
Nasopharyngeal Carcinoma
Double blind control period A140
Metastatic Colorectal Cancer
Sacituzumab Tirumotecan
Non-Small Cell Lung Cancer
SKB105 for injection Monotherapy
Advanced Solid Tumors
KN035
Solid Tumor
SI-B003
Esophageal Cancer
SKB571 for injection
Lung Cancer (Non-Small Cell)
Test product HY0001a for injection
Solid Tumor
GNC-035
Non-hodgkin's Lymphoma
Envafolimab+Lenvatinib
Advanced Endometrial Cancer
AP or TP
Non Small Cell Lung Cancer
SKB500 Powder for Injection
Small Cell Lung Cancer
Lenvatinib
Advanced Hepatocellular Carcinoma
GNC-038
Diffuse Large B-cell Lymphoma
SKB518
Lung Carcinoma
KL-A167 Injection
Nasopharyngeal Carcinoma
KL590586 Capsule
Advanced Solid Tumor
PD-1
Urothelial Carcinoma
Clarithromycin
Ovarian Epithelial Cancer
Test product: HYP-2090PTSA
Safety
HY05350 for injection
Advanced Solid Tumor
Envafolimab
Solid Tumor
BL-B01D1 for Injection
Recurrent Glioblastoma
Lenvatinib + Envafolimab
Solid Tumors
SKB518 for injection
Advanced Gynecological Malignancies
Osimertinib Mesylate Tablets
Non-small Cell Lung Cancer
BL-M02D1
Non-small Cell Lung Cancer
PD-1 monoclonal antibody
Extensive-stage Small-cell Lung Cancer
Axitinib
Renal Cancer
PRT-064040 nasal spray
Migraine
SKB103 for injection monotherapy
Advanced Solid Tumors
Cisplatin
Non-small Cell Lung Cancer
Low Dose PRT042 nasal spray
Major Depressive Disorder (MDD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Wujia Yizhi granules | Phase 3 | Alzheimer's Dementia | - | - |
Nab-paclitaxel | Phase 3 | Triple Negative Breast Cancer | - | - |
Topotecan | Phase 3 | Small Cell Lung Cancer | - | - |
HSK3486 | Phase 3 | Sedation or Anesthesia | - | - |
Capecitabine | Phase 3 | Metastatic Breast Cancer | - | - |
Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel | Phase 3 | HER2-low Breast Cancer | - | - |
Docetaxel | Phase 3 | Non-small Cell Lung Cancer | - | - |
Docetaxel or Paclitaxel | Phase 3 | Urothelial Carcinoma | - | - |
Eribulin | Phase 3 | HR+HER2- Breast Cancer | - | - |
Propofol | Phase 3 | Colonoscopy | - | - |
Paclitaxel | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
SKB264 | Phase 3 | Metastatic Breast Cancer | - | - |
Pemetrexed | Phase 3 | Non-small Cell Lung Cancer | - | - |
Osimertinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Vinorelbine | Phase 3 | Triple-Negative Breast Cancer | - | - |
SI-B001 | Phase 3 | Non-small Cell Lung Adenocarcinoma | - | - |
BL-M07D1 | Phase 3 | Her2-positive/Low-expression Urinary and Digestive Tract Tumors | - | - |
A166 | Phase 3 | HER2-positive Breast Cancer | - | - |
Irinotecan | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
T-DM1 | Phase 3 | HER2-positive Breast Cancer | - | - |
gemcitabine | Phase 3 | Nasopharyngeal Carcinoma | - | - |
KN035 plus Gemcitabine & oxaliplatin | Phase 3 | Biliary Tract Neoplasms | - | - |
Investigator's choice of chemotherapy | Phase 3 | Gastric Adenocarcinoma | - | - |
Pemetrexed+Cisplatin or Carboplatin | Phase 3 | Non-small Cell Lung Cancer | - | - |
BL-B01D1 | Phase 3 | Advanced Biliary Tract Cancer | - | - |
Carboplatin | Phase 3 | Non-squamous Non-small Cell Lung Cancer | - | - |
BL-M05D1 | Phase 3 | Gastric Cancer | - | - |
carboplatin or cisplatin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection | Phase 3 | Non-small Cell Lung Cancer | - | - |
Pertuzumab | Phase 3 | HER2-positive Breast Cancer | - | - |
KL-A167 | Phase 3 | Nasopharyngeal Carcinoma | - | - |
Double blind control period A140 | Phase 3 | Metastatic Colorectal Cancer | - | - |
Sacituzumab Tirumotecan | Phase 2 | Non-Small Cell Lung Cancer | - | - |
SKB105 for injection Monotherapy | Phase 2 | Advanced Solid Tumors | - | - |
KN035 | Phase 2 | Solid Tumor | - | - |
SI-B003 | Phase 2 | Esophageal Cancer | - | - |
SKB571 for injection | Phase 2 | Lung Cancer (Non-Small Cell) | - | - |
Test product HY0001a for injection | Phase 2 | Solid Tumor | - | - |
GNC-035 | Phase 2 | Non-hodgkin's Lymphoma | - | - |
Envafolimab+Lenvatinib | Phase 2 | Advanced Endometrial Cancer | - | - |
AP or TP | Phase 2 | Non Small Cell Lung Cancer | - | - |
SKB500 Powder for Injection | Phase 2 | Small Cell Lung Cancer | - | - |
Lenvatinib | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
GNC-038 | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
SKB518 | Phase 2 | Lung Carcinoma | - | - |
KL-A167 Injection | Phase 2 | Nasopharyngeal Carcinoma | - | - |
KL590586 Capsule | Phase 2 | Advanced Solid Tumor | - | - |
PD-1 | Phase 2 | Urothelial Carcinoma | - | - |
Clarithromycin | Phase 2 | Ovarian Epithelial Cancer | - | - |
Test product: HYP-2090PTSA | Phase 2 | Safety | - | - |
HY05350 for injection | Phase 2 | Advanced Solid Tumor | - | - |
Envafolimab | Phase 2 | Solid Tumor | - | - |
BL-B01D1 for Injection | Phase 2 | Recurrent Glioblastoma | - | - |
Lenvatinib + Envafolimab | Phase 2 | Solid Tumors | - | - |
SKB518 for injection | Phase 2 | Advanced Gynecological Malignancies | - | - |
Osimertinib Mesylate Tablets | Phase 2 | Non-small Cell Lung Cancer | - | - |
BL-M02D1 | Phase 2 | Non-small Cell Lung Cancer | - | - |
PD-1 monoclonal antibody | Phase 2 | Extensive-stage Small-cell Lung Cancer | - | - |
Axitinib | Phase 2 | Renal Cancer | - | - |
PRT-064040 nasal spray | Phase 2 | Migraine | - | - |
SKB103 for injection monotherapy | Phase 2 | Advanced Solid Tumors | - | - |
Cisplatin | Phase 2 | Non-small Cell Lung Cancer | - | - |
Low Dose PRT042 nasal spray | Phase 2 | Major Depressive Disorder (MDD | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR's drug pipeline?→
CatalystAlert tracks 63 drug candidates in Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR's (SKBBY) pipeline across Phase 3, Phase 2. Its lead program is Wujia Yizhi granules (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR's next FDA catalyst?→
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR's (SKBBY) next tracked catalyst is a Phase 2 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SKBBY biotech catalysts?→
Add SKBBY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.